Shah Pritesh - 03 Mar 2022 Form 4 Insider Report for NovoCure Ltd (NVCR)

Role: Chief Commercial Officer
Signature: By: /s/ Steven Robbins, Attorney in fact for Pritesh Shah
Issuer symbol: NVCR
Transactions as of: 03 Mar 2022
Net transactions value: +$3,164,688
Form type: 4
Filing time: 07 Mar 2022, 17:23:57 UTC
Previous filing: 07 Sep 2021
Next filing: 09 Mar 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NVCR	Ordinary Shares	Award	$0	+21,714	+30%	$0.000000	95,226	03 Mar 2022	Direct	F1
transaction	NVCR	Ordinary Shares	Sale	$74,275	-997	-1%	$74.50	94,229	03 Mar 2022	Direct	F2
transaction	NVCR	Ordinary Shares	Sale	$193,031	-2,632	-2.8%	$73.34	91,597	04 Mar 2022	Direct	F2
transaction	NVCR	Ordinary Shares	Sale	$134,759	-1,914	-2.1%	$70.41	89,683	04 Mar 2022	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NVCR	Options to Buy Ordinary Shares	Award	$3,064,596	+38,027		$80.59	38,027	03 Mar 2022	Ordinary Shares	38,027	$80.59	Direct	F3
transaction	NVCR	Options to Buy Ordinary Shares	Award	$502,156	+6,231		$80.59	6,231	03 Mar 2022	Ordinary Shares	6,231	$80.59	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted share units that are scheduled to vest in equal installments on each of March 21, 2023, 2024 and 2025, subject to the reporting person's continued employment through such dates.
F2	Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F3	Options to buy 38,027 ordinary shares will vest and become exercisable in equal installments on each of March 1, 2023, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates.
F4	Options to buy 6,231 ordinary shares will vest and become exercisable in equal installments on each of March 1, 2023 and 2024, subject to the reporting person's continued employment through such dates.